These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 12898010

  • 1. The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus.
    Williams RM, Amin R, Shojaee-Moradie F, Umpleby AM, Acerini CL, Dunger DB.
    Diabetologia; 2003 Sep; 46(9):1203-10. PubMed ID: 12898010
    [Abstract] [Full Text] [Related]

  • 2. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
    Acerini CL, Harris DA, Matyka KA, Watts AP, Umpleby AM, Russell-Jones DL, Dunger DB.
    Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
    [Abstract] [Full Text] [Related]

  • 3. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM, Yuen K, White D, Mallard B, Dalton RN, Acerini CL, Dunger DB.
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [Abstract] [Full Text] [Related]

  • 4. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T, Amin R, Williams RM, Fox C, Yuen KC, White MA, Umpleby AM, Acerini CL, Dunger DB.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [Abstract] [Full Text] [Related]

  • 5. Increasing urine albumin excretion is associated with growth hormone hypersecretion and reduced clearance of insulin in adolescents and young adults with type 1 diabetes: the Oxford Regional Prospective Study.
    Amin R, Williams RM, Frystyk J, Umpleby M, Matthews D, Orskov H, Dalton RN, Dunger DB.
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):137-44. PubMed ID: 15670188
    [Abstract] [Full Text] [Related]

  • 6. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
    Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB.
    Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
    [Abstract] [Full Text] [Related]

  • 7. Insulin sensitivity and lipolysis in adolescent girls with poorly controlled type 1 diabetes: effect of anticholinergic treatment.
    Halldin MU, Brismar K, Tuvemo T, Gustafsson J.
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):735-43. PubMed ID: 12460323
    [Abstract] [Full Text] [Related]

  • 8. Contrasting metabolic effects of continuous and pulsatile growth hormone administration in young adults with type 1 (insulin-dependent) diabetes mellitus.
    Pal BR, Phillips PE, Matthews DR, Dunger DB.
    Diabetologia; 1992 Jun; 35(6):542-9. PubMed ID: 1612227
    [Abstract] [Full Text] [Related]

  • 9. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes.
    Simpson HL, Jackson NC, Shojaee-Moradie F, Jones RH, Russell-Jones DL, Sönksen PH, Dunger DB, Umpleby AM.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):425-32. PubMed ID: 14715881
    [Abstract] [Full Text] [Related]

  • 10. The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus.
    Cheetham TD, Jones J, Taylor AM, Holly J, Matthews DR, Dunger DB.
    Diabetologia; 1993 Jul; 36(7):678-81. PubMed ID: 8359587
    [Abstract] [Full Text] [Related]

  • 11. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp.
    Carroll PV, Christ ER, Umpleby AM, Gowrie I, Jackson N, Bowes SB, Hovorka R, Croos P, Sönksen PH, Russell-Jones DL.
    Diabetes; 2000 May; 49(5):789-96. PubMed ID: 10905488
    [Abstract] [Full Text] [Related]

  • 12. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
    Higham CE, Rowles S, Russell-Jones D, Umpleby AM, Trainer PJ.
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
    [Abstract] [Full Text] [Related]

  • 13. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM.
    Carroll PV, Umpleby M, Ward GS, Imuere S, Alexander E, Dunger D, Sönksen PH, Russell-Jones DL.
    Diabetes; 1997 Sep; 46(9):1453-8. PubMed ID: 9287046
    [Abstract] [Full Text] [Related]

  • 14. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [Abstract] [Full Text] [Related]

  • 15. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults.
    Yuen K, Frystyk J, Umpleby M, Fryklund L, Dunger D.
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3956-64. PubMed ID: 15292333
    [Abstract] [Full Text] [Related]

  • 16. Intramuscular triglyceride content is increased in IDDM.
    Ebeling P, Essén-Gustavsson B, Tuominen JA, Koivisto VA.
    Diabetologia; 1998 Jan; 41(1):111-5. PubMed ID: 9498639
    [Abstract] [Full Text] [Related]

  • 17. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH.
    Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF.
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2098-103. PubMed ID: 10372717
    [Abstract] [Full Text] [Related]

  • 18. Low-dose IGF-I has no selective advantage over insulin in regulating glucose metabolism in hyperglycemic depancreatized dogs.
    Fisher SJ, Shi ZQ, Lickley HL, Efendic S, Vranic M, Giacca A.
    J Endocrinol; 2001 Jan; 168(1):49-58. PubMed ID: 11139769
    [Abstract] [Full Text] [Related]

  • 19. Insulin resistance in multiple tissues in patients with type 1 diabetes mellitus on long-term continuous subcutaneous insulin infusion therapy.
    Donga E, van Dijk M, Hoogma RP, Corssmit EP, Romijn JA.
    Diabetes Metab Res Rev; 2013 Jan; 29(1):33-8. PubMed ID: 22936679
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans.
    Laager R, Ninnis R, Keller U.
    J Clin Invest; 1993 Oct; 92(4):1903-9. PubMed ID: 8408642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.